New hope for tough pancreatic cancer: experimental combo tested

NCT ID NCT07235202

First seen Nov 19, 2025 · Last updated May 30, 2026 · Updated 23 times

Summary

This study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults with this type of cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tsinghua Changgung Hospital

    RECRUITING

    Beijing, Beijing Municipality, 102218, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Harbin Medical University Cancer Hospital

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, 150081, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510000, China

  • The First Hospital of Jilin University

    NOT_YET_RECRUITING

    Changchun, Jilin, 130015, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.